Kazia Therapeutics

Overview
Price performance
Financials
Research
Thematics

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

Healthcare |
Flash note

01.02.23

Kazia Therapeutics — Reinvestment period with increased R&D focus

Healthcare |
ADR Flash

19.12.22

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Healthcare |
Update

07.12.22

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Healthcare |
Flash note

01.11.22

Kazia Therapeutics — Q123 cash flows in line with our estimates

Visit Website

Balance Sheet

Forecast net debt (US$m)

Forecast gearing ratio (%)

224

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	7.1	28.2	(77.5)
Relative	3.2	19.1	(78.4)
52 week high/low	US$6.0/US$0.5

Financials

Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical efforts towards exploring the applicability and efficacy of paxalisib in non-central nervous system (CNS) oncology indications such as melanoma and other solid tumors, including breast cancer. Post-period, Kazia announced a A$4.5m fund-raise through a two-stage private placement of 40.9m new shares (25.4m unconditional shares and 15.5m conditional shares) at A$0.11 per share. Management intends to use the proceeds to support its development programs (including the paxalisib GBM AGILE study due to readout in H2 CY23) and working capital requirements. The period-end net cash balance stood at A$4.4m and this, along with the A$4.5m fund-raise, should provide headroom into H2 CY23, based on current burn rates.

Y/E Jun	Revenue (US$m)	EBITDA (US$m)	PBT (US$m)	EPS (fd) (c)	P/E (x)	P/CF (x)
2021A	10.7	(3.1)	(3.1)	(25.09)	N/A	N/A
2022A	0.0	(14.9)	(14.9)	(110.57)	N/A	N/A
2023E	0.0	(19.0)	(19.0)	(111.41)	N/A	N/A
2024E	10.8	(17.2)	(17.2)	(82.84)	N/A	N/A

Research

Flash note

Healthcare

21.06.22

Kazia Therapeutics — Paxalisib receives ODD for AT/RT

ADR Update

Healthcare

24.05.22

Kazia Therapeutics — Deep dive into childhood brain cancer

Healthcare

edison tv

29.06.22

Kazia Therapeutics webinar – Combating childhood brain cancer

edison tv

Healthcare

11.05.22

EVT801, Kazia’s second programme, and capital markets

edison tv

Healthcare

10.05.22

Paxalisib: Beyond glioblastoma and commercial opportunity

edison tv

Healthcare

09.05.22

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

ADR Update

Healthcare

28.03.22

Kazia Therapeutics — Several upcoming catalysts

edison tv

Healthcare

10.02.22

Kazia Therapeutics: Edison Open House Healthcare 2022

edison tv

Healthcare

25.10.21

Kazia Therapeutics – introducing novel asset EVT-801

ADR Update

Healthcare

14.10.21

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Update

Healthcare

13.10.21

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

edison tv

Healthcare

19.05.21

Kazia Therapeutics – overview and update with CEO James Garner

ADR Update

Healthcare

20.04.21

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Update

Healthcare

19.04.21

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

ADR Update

Healthcare

30.03.21

Kazia Therapeutics — Paxalisib Chinese rights licensed

Update

Healthcare

29.03.21

Kazia Therapeutics — Paxalisib Chinese rights licensed

ADR Update

Healthcare

08.03.21

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Update

Healthcare

01.03.21

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

edison tv

Healthcare

03.02.21

Kazia Therapeutics – Edison Open House interview

ADR Update

Healthcare

11.12.20

Kazia Therapeutics — Cantrixil final Phase I data reported

Update

Healthcare

10.12.20

Kazia Therapeutics — Cantrixil final Phase I data reported

ADR Update

Healthcare

02.12.20

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Update

Healthcare

24.11.20

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Initiation

Healthcare

28.08.20

Kazia Therapeutics — Bringing a vetted drug class to the brain

Update

Healthcare

31.03.20

Kazia Therapeutics — Paxalisib trial still on track for H220 start

ADR Update

Healthcare

13.01.20

Kazia Therapeutics — An agile pivot

Update

Healthcare

13.01.20

Kazia Therapeutics — An agile pivot

ADR Update

Healthcare

02.12.19

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

edison tv

Healthcare

25.11.19

Executive interview – Kazia Therapeutics

Update

Healthcare

25.11.19

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Update

Healthcare

05.09.19

Kazia Therapeutics — GDC-0084 gets a fifth collaboration

ADR Outlook

Healthcare

21.06.19

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Outlook

Healthcare

21.06.19

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

ADR Update

Healthcare

01.04.19

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Update

Healthcare

29.03.19

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

ADR Update

Healthcare

29.10.18

Kazia Therapeutics — New indications for GDC-0084

Update

Healthcare

29.10.18

Kazia Therapeutics — New indications for GDC-0084

ADR Update

Healthcare

19.09.18

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Update

Healthcare

19.09.18

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Outlook

Healthcare

13.05.18

Kazia Therapeutics — GDC-0084 Phase II underway

ADR Outlook

Healthcare

11.05.18

Kazia Therapeutics — GDC-0084 Phase II underway

Update

Healthcare

11.09.17

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Update

Healthcare

11.09.17

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Outlook

Healthcare

25.05.17

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Outlook

Healthcare

22.05.17

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Update

Healthcare

31.10.16

Novogen — Update 31 October 2016

ADR Update

Healthcare

11.05.16

Novogen — Update 11 May 2016

Update

Healthcare

09.05.16

Novogen — Update 9 May 2016

thematic

Financials

20.09.24

Banco Angolano de Investimentos (BAI) – Money-centre bank with lending optionality

thematic

Industrials

28.08.24

The art of measurement – Challenges in metrology

thematic

Investment Companies

12.08.24

Vietnam Holding – Vietnam in the global digital race

thematic

Investment Companies

31.07.24

US small-cap equities – Time to shine?

thematic

TMT

29.07.24

MediaWatch – Encouragements and frustrations

thematic

Consumer

22.07.24

ConsumerWatch – The times they are a-changin’

thematic

Investment Companies

10.06.24

Emerging markets – Worthy of consideration

thematic

Investment Companies

06.06.24

Dynam Capital at the 2024 Vietnam ESG Conference

thematic

TMT

06.06.24

MediaWatch – Glimpses of positivity

thematic

Consumer

30.05.24

ConsumerWatch – Give me a reason to love you

thematic

Investment Companies

16.05.24

UK stock market – Scope for further upside in UK large-cap stocks

thematic

Investment Companies

06.03.24

Listed private equity – Performing a balancing act

thematic

Consumer

23.02.24

ConsumerWatch – At least someone loves me

thematic

TMT

02.02.24

MediaWatch – Rinse and repeat

thematic

Healthcare

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Financials

08.12.23

South African life assurers: Where is the growth?

thematic

Consumer

21.11.23

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

thematic

TMT

21.11.23

Deutsches Eigenkapitalforum (EKF) 2023 technology

thematic

Financials

20.11.23

Deutsches Eigenkapitalforum (EKF) 2023 financials and investment companies

thematic

Industrials

20.11.23

Deutsches Eigenkapitalforum (EKF) 2023 industrials

thematic

Healthcare

20.11.23

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

thematic

Healthcare

13.11.23

VolitionRx – Decoding the DNA of cancer

thematic

TMT

07.11.23

MediaWatch – Still waiting…

thematic

Consumer

30.10.23

ConsumerWatch – Falling into the fall

thematic

Metals & Mining

27.09.23

Shades of the 1970s

thematic

Industrials

04.09.23

The long and winding road

thematic

TMT

28.07.23

MediaWatch – Targeting the opportunities

thematic

Consumer

26.07.23

ConsumerWatch – Making the most of the summer

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

thematic

Financials

09.05.23

IFRS 17: Impact on life assurance companies

thematic

TMT

25.04.23

MediaWatch – Vision On

thematic

Consumer

21.04.23

ConsumerWatch – A Spring in the step

thematic

Industrials

13.04.23

Quantum computing: A booming industry

thematic

Metals & Mining

28.03.23

Critical minerals: The investment vacuum

thematic

Financials

17.03.23

Crypto, are you dead yet?

thematic

Industrials

27.02.23

UK housebuilders

thematic

Investment Companies

13.02.23

European equities

thematic

Investment Companies

08.02.23

Listed Private Equity

thematic

Metals & Mining

01.02.23

Lithium’s adolescence

Concept of energy storage unit consisting of multiple conected containers with batteries. 3d rednering.

thematic

Industrials

01.02.23

Battery energy storage

Digital Marketing and Internet Media Technology Platform

thematic

TMT

31.01.23

MediaWatch – Screening well

thematic

Investment Companies

27.01.23

Vietnamese equities: Due a comeback?

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Consumer

23.01.23

ConsumerWatch – January sales

thematic

Healthcare

06.01.23

Outlook for 2023: Biotechs remain central to novel drug development

thematic

Healthcare

04.01.23

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

thematic

Healthcare

20.12.22

Cell and gene therapies

thematic

Investment Companies

30.11.22

Investment companies: Latin America is worthy of consideration

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Real Estate

11.11.22

South African industrial property fundamentals are strong

thematic

Metals & Mining

08.11.22

Lepidico: Offer closes, oversubscribed

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Financials

03.11.22

UK motor P&C insurers series

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Real Estate

24.10.22

South African retail property funds remain resilient

thematic

Consumer

13.10.22

ConsumerWatch – Bargains galore

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

Consumer

03.10.22

Food tech – At the forefront of food innovation

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Consumer

18.07.22

ConsumerWatch – Value emerging

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Industrials

22.06.22

A new paradigm for space

thematic

Industrials

30.05.22

Geopolitical conflict to drive renewables surge

thematic

Industrials

25.05.22

The emergence of mega-constellations

thematic

Industrials

23.05.22

Internet in the sky

thematic

12.05.22

Global markets: Valuation ‘normalisation’ continues

thematic

Financials

11.05.22

Revisiting IPOs in London

thematic

TMT

11.05.22

Direct tech investors

thematic

Investment Companies

10.05.22

The case for US capital markets

thematic

Industrials

10.05.22

Truth creates light

thematic

Industrials

09.05.22

All-seeing eye in the sky

thematic

Metals & Mining

27.04.22

Five (more) things every investor should know about lithium and Lepidico

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

thematic

TMT

21.04.22

Seven things every investor needs to know about SenSen

thematic

20.04.22

The industrialisation of space

thematic

Industrials

01.04.22

Five things every investor should know about everyday decarbonisation and Itaconix

thematic

Industrials

01.04.22

Feeding the world

thematic

28.03.22

Global strategic insight: Still neutral on global equities, with caveats

thematic

Consumer

24.03.22

Circular economy business models

thematic

Metals & Mining

21.03.22

Decarbonisation – A potential opportunity for aluminium producers

thematic

Consumer

11.03.22

Seven things every investor should know about Unbound Group

thematic

Financials

11.03.22

04.02.22

Moving from a vegan January to a sustainable one

thematic

Industrials

02.02.22

BayWa – Focus on sustainability

thematic

19.01.22

Global perspectives: Earnings momentum still positive

thematic

Consumer

10.01.22

Cultivated meat – Engineering the growth of alternative meats

thematic

Metals & Mining

13.12.21

The PGM markets – Outlook and price forecasts

thematic

Industrials

13.12.21

Have yourself a sustainable little Christmas

thematic

01.12.21

Global perspectives – Omicron: A 2-week waiting game

thematic

Industrials

25.11.21

COP26: What does it mean for business?

thematic

25.11.21

Equity strategy and market outlook – November 2021

thematic

Healthcare

10.11.21

Artificial intelligence in drug discovery

thematic

Industrials

01.11.21

Investment themes: IPO boom in London

thematic

Energy & Resources

29.10.21

Demand for Teslas points to lithium deficit

thematic

Industrials

29.10.21

COP26: No matter the outcome, the private sector is the engine of change

thematic

28.10.21

Equity strategy and market outlook – October 2021

thematic

Industrials

28.10.21

29.09.21

09.09.21

06.09.21

The future of fish – The investment case for sustainable fishing

thematic

26.08.21

Equity strategy and market outlook – August 2021

thematic

Consumer

25.08.21

The growth of UK food ordering and delivery platform

thematic

Financials

23.08.21

28.07.21

Finding the sea of green – The opportunity and options for shipping green H2

thematic

Healthcare

27.07.21

Biosynthesis – Taking the cannabinoid market to new heights

thematic

20.07.21

Global equities: Volatility rises at the upper reaches of valuation

thematic

TMT

14.07.21

18.05.21

The circular economy

thematic

29.04.21

Equity strategy and market outlook – April 2021

thematic

Energy & Resources

28.04.21

Decarbonisation

thematic

Industrials

20.04.21

22.03.21

Seven things every investor should know about SIGA technologies & biological weapons

thematic

18.03.21

Global perspectives: Rising US bond yields? Value investors have little to fear

thematic

Real Estate

17.03.21

01.02.21

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

thematic

28.01.21

07.12.20

29.10.20

16.08.20

24.06.20

08.04.20

27.02.20

12.12.19

30.10.19

Edison Exhibits- antibiotic development

thematic

24.10.19

Past the peak of political risk?

thematic

Industrials

17.10.19

Water – The real liquidity crisis

thematic

17.10.19

Illuminator – October Update

thematic

Industrials

16.10.19

14.08.19

Illuminator: August Update

thematic

14.08.19

Staying focused on the facts – the risks remain in place

thematic

Investment Companies

07.08.19

Post Woodford- A spotlight on smaller company liquidity

thematic

TMT

05.08.19

European video games

thematic

25.07.19

Equity strategy and market outlook – July 2019

thematic

Healthcare

17.07.19

10.07.19

Diversification and scale for online success

thematic

Financials

03.07.19

26.06.19

18.06.19

The A-B-T of biosimilars- Explaining contemporary life science issues

thematic

Healthcare

10.06.19

Cannabinoid Therapies- The coming retail wave

thematic

06.06.19

Could the US Fed be enabling a continuation of the trade war?

thematic

Investment Companies

05.06.19

22.05.19

Cannabinoid Therapies- Therapeutics turning a corner

thematic

20.05.19

Shifting trade politics should not be ignored

thematic

Metals & Mining

16.05.19

Alliance Mineral Assets secures strategic investment from Galaxy and Jiangxi

thematic

Financials

14.05.19

Time value of money

thematic

TMT

08.05.19

24.04.19

Piedmont Lithium increases its mineral resource estimate by 21%

thematic

18.04.19

Equity strategy and market outlook – April 2019

thematic

Financials

15.04.19

Cash flow

thematic

09.04.19

Stronger survey data quashes recession fears for now

thematic

Healthcare

08.04.19

Trial outcomes and value – Explaining contemporary clinical trial issues

thematic

08.04.19

Industrial Automation

thematic

Energy & Resources

03.04.19

26.03.19

Types of investment trusts

thematic

21.03.19

Brexit: EU can do it if you really want…

thematic

Energy & Resources

20.03.19

Orinduik resource upgrade for Eco Atlantic offshore Guyana

thematic

14.03.19

Brexit: PM May’s deal may finally be in sight

thematic

Energy & Resources

13.03.19

No moveable hydrocarbons in Alaskan Winx-1 well

thematic

Energy & Resources

12.03.19

04.03.19

26.02.19

UK video games – Heterogeneous not homogeneous

thematic

14.02.19

Market outlook: balanced but still biased to upside

thematic

Financials

08.02.19

Enterprise versus equity valuation

thematic

Healthcare

29.01.19

The diagnostics sector

thematic

28.01.19

ECB fiddles as eurozone turns

thematic

Metals & Mining

22.01.19

Gold stars and black holes

thematic

Financials

15.01.19

Deutsche Börse’s Scale

thematic

Financials

08.01.19

20.11.18

25.09.18

04.09.18

Tullow spuds Cormorant well offshore Namibia

thematic

Energy & Resources

20.08.18

Southern gas corridor to the EU nears agreement

thematic

13.08.18

Turkey:When risks collide

thematic

Energy & Resources

01.08.18

28.03.18

07.02.18

13.12.17

Kosmos exploration hiccups

thematic

Energy & Resources

06.12.17

Positive news from Genel’s Taq Taq

thematic

24.11.17

Economic surprise accelerating

thematic

Energy & Resources

20.11.17

Ludicrous growth of the EV

thematic

Energy & Resources

07.11.17

Tullow’s Araku result completes our 2017 wells to watch list

thematic

Energy & Resources

16.10.17

Fancy a Ferrari or an EV?

thematic

Energy & Resources

10.10.17

Verbier delivers after sidetrack

thematic

09.10.17

Economic data surprising to the upside in Q3

thematic

Energy & Resources

03.10.17

Revealing Big Oil hurdle rates

thematic

28.09.17

Earnings momentum – 2017 forecasts drifting slowly lower

thematic

Energy & Resources

26.09.17

Fatala well latest disappointment offshore West Africa

thematic

Energy & Resources

18.09.17

Partridge and Verbier fail to find oil

thematic

12.09.17

Interesting times for central bankers

thematic

Energy & Resources

17.08.17

08.08.17

Kosmos searching for more investors

thematic

Energy & Resources

26.07.17

21.06.17

ASCO 2017

thematic

21.06.17

Equity risks are rising: economic surprises turning lower

thematic

Energy & Resources

20.06.17

07.06.17

Porcupine Basin attracts Total

thematic

Energy & Resources

26.05.17

02.05.17

Cairn/FAR return to deepwater FAN in Senegal

thematic

24.04.17

French Election: Is populism already passé?

thematic

Energy & Resources

12.04.17

01.03.17

What a difference a year makes

thematic

TMT

24.02.17

15.02.17

Filicudi discovery – positive start to 2017 Barents exploration

thematic

Energy & Resources

10.02.17

Tullow dipping a toe back into exploration

thematic

TMT

08.02.17

Mobile ecosystems

thematic

Energy & Resources

06.02.17

Diversified Gas and Oil – quick thoughts

thematic

03.02.17

Implicit forward guidance on asset prices?

thematic

Energy & Resources

27.01.17

24.11.16

Fortuna LNG deal underlines the structurally higher costs of capital seen by E&Ps

thematic

Energy & Resources

24.11.16

12.10.16

Development lead times

thematic

Energy & Resources

27.09.16

17.08.16

27.07.16

SDX initiation

thematic

22.07.16

UK earnings trends – stable and few surprises

thematic

Energy & Resources

19.07.16

Porcupine Basin Phase 2

thematic

Energy & Resources

18.07.16

09.06.16

27.04.16

18.03.16

02.03.16

Genel’s Taq Taq highlights complexity of fractured reservoirs

thematic

Energy & Resources

23.02.16

02.02.16

Oil Macro outlook 2016 – oversupply in the short term

thematic

Energy & Resources

27.01.16

Oil & gas macro outlook – Oversupply short term, lower break-even long term

thematic

19.01.16

Global market sell-off-are we nearly there yet

thematic

Energy & Resources

12.01.16

Governments need to adapt to the oil price too

thematic

Energy & Resources

11.01.16

17.11.15

29.10.15

Falklands exploration: Humpback results finally in

thematic

Energy & Resources

28.10.15

Is the Serica deal a sign of improved North Sea co-operation?

thematic

Energy & Resources

20.10.15

Genel trading statement

thematic

Energy & Resources

16.10.15

Is there a link between the oil prices and deals?

thematic

Energy & Resources

15.10.15

Kurdistan payments ~ two payments in two months

thematic

TMT

13.10.15

Mobile ecosystems

thematic

Energy & Resources

15.09.15

Plexus Holdings taps subsea market

thematic

Energy & Resources

27.08.15

Gulf of Mexico – stepping up to the challenges

thematic

Energy & Resources

03.08.15

Kurdistan ~ payments coming

thematic

Energy & Resources

27.07.15

Petroceltic ~ Creating value in Algeria through execution

thematic

Energy & Resources

27.07.15

Cairn ~ Exposure to Senegal exploration, at lower risk

thematic

Energy & Resources

27.07.15

Rockhopper ~ Building a full cycle, exploration-led E&P

thematic

Energy & Resources

14.07.15

Wentworth Resources ~ company snapshot

thematic

Energy & Resources

13.07.15

Genel operations update ~ still waiting for export payments

thematic

Energy & Resources

25.06.15

Company Snapshot ~ Sterling Energy

thematic

Energy & Resources

15.06.15

Company Snapshot ~ Solo Oil

thematic

Energy & Resources

22.05.15

What’s the marginal cost of oil supply – $60/bbl or $80/bbl?

thematic

Energy & Resources

07.05.15

Saudi-led market share war with US producers continues

thematic

Energy & Resources

01.05.15

Oil & gas macro outlook – The market is returning to equilibrium

thematic

Energy & Resources

07.04.15

First Falklands well in two years looks positive

thematic

Energy & Resources

26.03.15

Nigerian elections 28th March

thematic

TMT

23.03.15

NZ – Edison talks tech

thematic

TMT

23.03.15

AUS – Edison talks tech

thematic

Energy & Resources

19.03.15

Ophir results – Acting counter-cyclically… or not?

thematic

TMT

18.03.15

Mobile ecosystems

thematic

Energy & Resources

13.03.15

Reserves – better not blink or they could be gone

thematic

Energy & Resources

13.03.15

Omne trium perfectum

thematic

Energy & Resources

10.03.15

Thoughts post Cairn FY14 results & India tax update

thematic

Energy & Resources

05.03.15

Finite storage capacity could call time on the financial demand currently supporting oil prices

thematic

Energy & Resources

03.03.15

Exploration Watch – Falklands

thematic

Energy & Resources

25.02.15

Catalytic converter – Five themes from oil majors’ 2015 updates

thematic

Energy & Resources

25.02.15

Exploration watch – Drilling returns to the Falklands

thematic

Metals & Mining

06.02.15

Mining sector report: Gold: The value of gold and other metals

thematic

Energy & Resources

14.01.15

Oil & Gas – Macro Outlook: Current prices are not sustainable

thematic

Energy & Resources

03.12.14

Catalytic converter – Crude oil prices: A range-bound future

thematic

Industrials

24.11.14

Renewables rising – Sector primer

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

TMT

15.10.14

Mobile ecosystems

thematic

Energy & Resources

03.10.14

Oil & Gas – Macro Outlook: Swimming in oil

thematic

Energy & Resources

02.05.14

Oil & gas macro outlook: Ukraine supports prices for now

thematic

Healthcare

05.03.14

Edison healthcare quarterly: A boost for allergy immunotherapy

thematic

Energy & Resources

04.03.14

ASX Spotlight Conference – London, 6 March 2014

thematic

Metals & Mining

26.02.14

Making a case for uranium: Life after Fukushima

thematic

Metals & Mining

28.01.14

Indaba special, 2014

thematic

Energy & Resources

28.01.14

Oil & gas macro outlook: North America is shifting the supply needle

thematic

Energy & Resources

10.10.13

Fallen angels, rising stars: Old LatAm basins creating fresh opportunities

thematic

Energy & Resources

04.10.13

Oil & gas macro outlook: The market remains well supplied

thematic

Industrials

27.09.13

German Mittelstand Conference

thematic

Energy & Resources

14.08.13

Oil & Gas – Oil & gas research principles

thematic

Industrials

11.06.13

German industrials spotlight: Sand in the gears

thematic

Industrials

15.05.13

German industrials spotlight: Industrial machinery

thematic

Energy & Resources

08.05.13

Oil & Gas – Falklands oils: Time to pause and draw breath

thematic

Industrials

10.04.13

German industrials: Global ambitions

thematic

Energy & Resources

01.03.13

ASX Small to Mid Caps Conference – London, 7 March 2013

thematic

Energy & Resources

28.02.13

Asia-Pacific resources quarterly: February 2013 edition

thematic

26.02.13

Macro Outlook: Prices look vulnerable

thematic

Energy & Resources

08.02.13

Seismic reflections: Seismic Elections

thematic

Metals & Mining

01.02.13

Indaba special, 2013

thematic

Healthcare

07.12.12

Edison healthcare quarterly: Boom times for US biotech

thematic

Energy & Resources

16.11.12

Seismic reflections: Oil market dynamics turn bearish

thematic

06.11.12

Macro Outlook: North American supply gathers pace

thematic

Energy & Resources

05.10.12

Seismic reflections: Sentiment vs reality

thematic

Metals & Mining

02.10.12

Edison mining quarterly: October 2012

thematic

Metals & Mining

14.09.12

Mining catalyst: China’s new stimulus

thematic

Energy & Resources

07.09.12

Seismic reflections: Take me out

thematic

Healthcare

30.08.12

Edison healthcare quarterly: Crisis? What crisis?

thematic

Energy & Resources

24.08.12

Seismic reflections: Unstoppable force?

thematic

Energy & Resources

20.08.12

Asia-Pacific resources quarterly: August edition

thematic

Energy & Resources

10.08.12

Seismic reflections: Stick or twist – looks like twist

thematic

Energy & Resources

13.07.12

Seismic reflections: What’s next for UK North Sea?

thematic

Energy & Resources

15.06.12

Seismic reflections: The next major US resource play

thematic

Healthcare

28.05.12

Edison healthcare quarterly: How to please some of the people some of the time

thematic

Investment Companies

24.05.12

Investment Trusts Quarterly: Biotechnology & healthcare trusts

thematic

Energy & Resources

10.05.12

Asia-Pacific resources quarterly

thematic

Energy & Resources

04.05.12

Seismic reflections: Closing bell for the 27th UK licensing round

thematic

Metals & Mining

25.04.12

Edison mining quarterly: April 2012

thematic

24.04.12

Macro Outlook: Supply concerns wane

thematic

Energy & Resources

20.04.12

Seismic reflections: YPF nationalisation

thematic

Energy & Resources

05.04.12

Seismic reflections: Heavy cash

thematic

Energy & Resources

09.03.12

Seismic reflections: Budgeting for a North Sea revitalisation

thematic

13.02.12

Macro Outlook – Diverging Brent and WTI price trends

thematic

Energy & Resources

10.02.12

Seismic reflections: Italian drilling ban about turn?

thematic

Energy & Resources

27.01.12

Seismic reflections: Gas to liquids could gain traction

thematic

Investment Companies

13.01.12

Investment Trusts Quarterly: Growth and income

thematic

Energy & Resources

13.01.12

Seismic reflections: Funding troubles, M&A bubbles

thematic

Metals & Mining

16.12.11

Macro Outlook – Price weakness on the cards

thematic

Energy & Resources

28.10.11

Seismic reflections: Singing those 100% equity blues

thematic

26.10.11

Macro Outlook: Market backdrop still bearish

thematic

Metals & Mining

07.10.11

Indium and gallium overview

thematic

Energy & Resources

30.09.11

Seismic reflections: Enormous North American potential

thematic

Industrials

20.09.11

DSEi: Feedback and thoughts

thematic

Energy & Resources

16.09.11

Seismic reflections : Tullow’s breakthrough discovery

thematic

11.08.11

Macro Outlook – Rapidly weakening market backdrop

thematic

Energy & Resources

05.08.11

Seismic reflections: Confidence in Kurdistan grows

thematic

Energy & Resources

24.06.11

Seismic reflections: An exciting investment story

thematic

Energy & Resources

22.06.11

Still bearish

thematic

Metals & Mining

13.06.11

Switzerland: Global Resources Investing Conference

thematic

Energy & Resources

23.05.11

Seismic reflections : Commodity prices only a side issue

thematic

Energy & Resources

18.04.11

Crude market potentially vulnerable

thematic

Energy & Resources

01.04.11

Seismic reflections : Taxing matters

thematic

Energy & Resources

11.03.11

Seismic reflections – Introducing the oil screen

thematic

Energy & Resources

25.02.11

Supply fears exaggerated

thematic

TMT

24.09.10

The third pillar

thematic

TMT

10.09.10

The real disruptor

thematic

TMT

27.08.10

Merger mania is back

thematic

Energy & Resources

16.08.10

Equities

Equities by Sector

Sectors

Thematics

Latest

Healthcare-focused trusts: A sector on the mend

MediaWatch – One step forward, two steps back

ConsumerWatch – Don’t look down

Audiovisual

Latest

VEON – executive interview with CFO Joop Brakenhoff

VEON – executive interview with CEO Kaan Terzioğlu

World’s Toughest Row 2024

About Edison

About Edison

Careers

Kazia Therapeutics (NASDAQ: KZIA)

Latest Insights

Kazia Therapeutics — Reinvestment period with increased R&D focus

Kazia Therapeutics — Collaboration may expand utility to combo therapies

Kazia Therapeutics — EVT801 data published in peer-reviewed journal

Kazia Therapeutics — Q123 cash flows in line with our estimates

Balance Sheet

Share Price Performance

Financials

Research

Kazia Therapeutics — Paxalisib receives ODD for AT/RT

Kazia Therapeutics — Deep dive into childhood brain cancer

Kazia Therapeutics webinar – Combating childhood brain cancer

EVT801, Kazia’s second programme, and capital markets

Paxalisib: Beyond glioblastoma and commercial opportunity

Meet Kazia’s management team and hear about paxalisib, Kazia’s lead programme

Kazia Therapeutics — Several upcoming catalysts

Kazia Therapeutics: Edison Open House Healthcare 2022

Kazia Therapeutics – introducing novel asset EVT-801

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Kazia Therapeutics — Multiple paxalisib data points expected in Q4

Kazia Therapeutics – overview and update with CEO James Garner

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Kazia Therapeutics — New asset to target tumor lymphangiogenesis

Kazia Therapeutics — Paxalisib Chinese rights licensed

Kazia Therapeutics — Paxalisib Chinese rights licensed

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Kazia Therapeutics — All in on GBM AGILE, but eyes on brain mets

Kazia Therapeutics – Edison Open House interview

Kazia Therapeutics — Cantrixil final Phase I data reported

Kazia Therapeutics — Cantrixil final Phase I data reported

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Kazia Therapeutics — Phase IIa shows good safety, consistent efficacy

Kazia Therapeutics — Bringing a vetted drug class to the brain

Kazia Therapeutics — Paxalisib trial still on track for H220 start

Kazia Therapeutics — An agile pivot

Kazia Therapeutics — An agile pivot

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Executive interview – Kazia Therapeutics

Kazia Therapeutics — GDC-0084 – encouraging initial efficacy

Kazia Therapeutics — GDC-0084 gets a fifth collaboration

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Kazia Therapeutics — Higher MTD, new collaboration for GDC-0084

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Kazia Therapeutics — Cantrixil efficacy data presented at AACR

Kazia Therapeutics — New indications for GDC-0084

Kazia Therapeutics — New indications for GDC-0084

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Kazia Therapeutics — GDC-0084 and Cantrixil trials progressing

Kazia Therapeutics — GDC-0084 Phase II underway

Kazia Therapeutics — GDC-0084 Phase II underway

Novogen — GDC-0084 Phase II on track to commence Q417

Novogen — GDC-0084 Phase II on track to commence Q417

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Novogen — Update 31 October 2016

Novogen — Update 11 May 2016

Novogen — Update 9 May 2016

Banco Angolano de Investimentos (BAI) – Money-centre bank with lending optionality

The art of measurement – Challenges in metrology

Vietnam Holding – Vietnam in the global digital race

US small-cap equities – Time to shine?

MediaWatch – Encouragements and frustrations

ConsumerWatch – The times they are a-changin’